Novel insights into STAT3 in renal diseases

• Published in: Biomedicine & pharmacotherapy Vol. 165; p. 115166
• Main Authors: Yu, Ju-tao, Fan, Shuai, Li, Xiang-yu, Hou, Rui, Hu, Xiao-wei, Wang, Jia-nan, Shan, Run-run, Dong, Ze-hui, Xie, Man-man, Dong, Yu-hang, Shen, Xiao-yu, Jin, Juan, Wen, Jia-gen, Liu, Ming-ming, Wang, Wei, Meng, Xiao-ming
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.09.2023; Elsevier
• Subjects: AKI; Post-translational modifications; Renal diseases; STAT3; Renal diseases; DN; Post-translational modifications; STAT3; AKI
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.115166

Signal transducer and activator of transcription 3 (STAT3) is a cell-signal transcription factor that has attracted considerable attention in recent years. The stimulation of cytokines and growth factors can result in the transcription of a wide range of genes that are crucial for several cellular biological processes involved in pro- and anti-inflammatory responses. STAT3 has attracted considerable interest as a result of a recent upsurge in study because of their role in directing the innate immune response and sustaining inflammatory pathways, which is a key feature in the pathogenesis of many diseases, including renal disorders. Several pathological conditions which may involve STAT3 include diabetic nephropathy, acute kidney injury, lupus nephritis, polycystic kidney disease, and renal cell carcinoma. STAT3 is expressed in various renal tissues under these pathological conditions. To better understand the role of STAT3 in the kidney and provide a theoretical foundation for STAT3-targeted therapy for renal disorders, this review covers the current work on the activities of STAT3 and its mechanisms in the pathophysiological processes of various types of renal diseases. •STAT3 can be activated by JAKs, RTKs and other non-receptor tyrosine kinase signaling pathways in the renal disease.•STAT3 is negatively regulated by three types of regulators: SOCS, PTPs and PIAS in the renal disease.•The STAT3 signalling appears to be a promising drug target for DN treatment.